KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Humana (HUM) EBITDA (2016 - 2025)

Humana (HUM) has disclosed EBITDA for 16 consecutive years, with -$1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA changed N/A to -$1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 billion, a N/A change, with the full-year FY2025 number at $3.5 billion, up 35.71% from a year prior.
  • EBITDA was -$1.5 billion for Q4 2025 at Humana, down from $591.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $3.0 billion in Q3 2021 to a low of -$1.5 billion in Q4 2025.
  • A 4-year average of $1.0 billion and a median of $1.4 billion in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 131.76% in 2021, then skyrocketed 272.36% in 2022.
  • Humana's EBITDA stood at $233.0 million in 2021, then skyrocketed by 36.48% to $318.0 million in 2022, then surged by 279.25% to $1.2 billion in 2023, then tumbled by 221.97% to -$1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for HUM's EBITDA are -$1.5 billion (Q4 2025), $591.0 million (Q3 2025), and $1.1 billion (Q2 2025).